Comphya SA, a pioneering medical technology company and the developer of CaverSTIM, the first implantable neuromodulator designed to treat erectile dysfunction announced recently the successful closure of the first tranche of its Series A1 funding round. This achievement strengthens Comphya’s financial position, enabling the continued advancement and expansion of its groundbreaking clinical trials..

Comphya SA是一家先锋医疗技术公司，也是首个治疗勃起功能障碍的可植入神经调节器CaverSTIM的开发者，近期宣布成功完成了其A1系列首轮融资。这一成就巩固了Comphya的财务地位，使其能够持续推进和扩展其突破性的临床试验。

The total funding of CHF 4.35 million includes a combination of converted Convertible Loan and newly raised equity capital. The proceeds from this funding round will be instrumental in advancing our clinical trials across Australia, Brazil, and the United States, which have already demonstrated promising results. .

总融资额435万瑞士法郎，包括转换后的可转换贷款和新筹集的股权资本。这笔融资的收益将有助于推动我们在澳大利亚、巴西和美国的临床试验，这些试验已经显示出令人鼓舞的结果。

“This new funding positions Comphya to accelerate the delivery of our groundbreaking solution to restore erectile function, while driving significant value for patients and stakeholders,” said Dr. Rodrigo Fraga, CEO of

“这笔新的资金使Comphya能够加快推出我们突破性的恢复勃起功能的解决方案，同时为患者和利益相关者带来显著的价值，”Comphya首席执行官罗德里戈·弗拉加博士表示。

Comphya

康菲亚

. “We deeply appreciate the trust and confidence our investors have placed in our vision and mission.”

“我们深深感激投资者对我们愿景和使命的信任与信心。”

Dr. Steve Swinson, Chairman of the Board, added, “This achievement is a testament to the unwavering dedication of our team, the trust of our investors, and the invaluable support of our key opinion leaders, including Prof. Arthur Burnett, Prof. Anthony Costello, Prof. Sidney Glina, and Dr. Phil Dundee.

董事长史蒂夫·斯温森博士补充说：“这一成就证明了我们团队的坚定奉献精神、投资者的信任以及包括亚瑟·伯内特教授、安东尼·科斯特洛教授、西德尼·格利纳教授和菲尔·邓迪博士在内的关键意见领袖的宝贵支持。

We extend our heartfelt gratitude to everyone who has contributed to Comphya’s success.”.

我们衷心感谢所有为Comphya的成功做出贡献的人。

Treating erectile dysfunction caused by mechanical nerve damage

治疗由机械性神经损伤引起的勃起功能障碍

CaverSTIM is the first implantable neurostimulator designed to restore erectile function. This innovative technology is primarily intended for patients who are non-responders to oral medications, such as post-prostatectomy patients. CaverSTIM is a neurostimulation system composed of an implantable pulse generator (IPG) containing a rechargeable battery and electronics responsible for generating the electrostimulation signal.

CaverSTIM 是首款旨在恢复勃起功能的可植入神经刺激器。这项创新技术主要针对对口服药物无反应的患者，例如前列腺切除术后的患者。CaverSTIM 是一个神经刺激系统，由包含可充电电池和负责生成电刺激信号的电子元件的可植入脉冲发生器 (IPG) 组成。

It is connected to an array of two electrodes (with multiple individual electrodes) to be implanted in the pelvic cavity, where they will activate and restore the nerves responsible for penile erection..

它连接到一组两个电极（具有多个单独电极），这些电极将被植入盆腔，激活并恢复负责阴茎勃起的神经。

(PR)

（公共关系）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送